Highly interesting events on transglutaminase, celiac disease, thromoprophylaxis or other related topics.
Please contact us in advance to make an appointment to meet at the venue.



MEDICA
12. November 2019

Location Düsseldorf, Germany
External Link MEDICA
Comment Meet Dr. Martin Hils and Dr. Ralf Paternack at the venue.
 
 
New Frontiers Symposium
23. November 2019

Location Chicago, USA
External Link cureceliacdisease
Comment Physicians, researchers, dietitians, nurses, and patients are welcome to this event!
 
 
World ADC London 2020
02. March 2020 - 05. March 2020

Location London, Great Britain
External Link ADC
Comment Meet Dr. Martin Hils at the venue!
 
 
Celiac Disease Center's International Symposium
06. March 2020 - 07. March 2020

Location New York, USA
External Link calendar
Comment Join an international symposium organized by the Celiac Disease Center at Columbia University.
 
 
Gordon Research Conference - Transglutaminases in Human Disease Processes
14. June 2020 - 19. June 2020

Location Mount Snow, USA
External Link GRC
Comment Meet Dr. Ralf Pasternack and Dr. Martin Hils at the venue.
 
 

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageZedira ISO9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • MEDICA

    12.11.2019
    Düsseldorf, Germany

  • New Frontiers Symposium

    23.11.2019
    Chicago, USA

  • World ADC London 2020

    02.03.2020 - 05.03.2020
    London, Great Britain

  • Celiac Disease Center's International Symposium

    06.03.2020 - 07.03.2020
    New York, USA

  • Gordon Research Conference - Transglutaminases in Human Disease Processes

    14.06.2020 - 19.06.2020
    Mount Snow, USA